Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer

Inclusion Criteria:

1. Provide written informed consent prior to screening

2. Male or female patients, age ≥ 18 years

3. Histologically or cytologically confirmed diagnosis of NSCLC

4. Stage IV disease (including patients with pleural effusion previously classified as
Stage IIIB)

5. All of the following if patient has had prior radiation therapy:

- lesion(s) used for determination of response were not previously irradiated or
have increased in size since the completion of radiotherapy

- the patient has recovered from any acute effects of the radiotherapy

- radiotherapy was completed at least 4 weeks prior to screening

6. Part 1: Have at least non-measurable evaluable disease (e.g., lesions which are
smaller than the minimum size required for measurability; other non-measurable
lesions such as bone metastases, malignant pleural effusion)

7. Part 2: Have measurable disease, defined as at least 1 lesion that can be accurately
measured in at least 1 dimension (longest diameter to be recorded) as > 10
millimeters (mm) on cross-sectional imaging (where the CT slice thickness is no
greater than 5 mm) or at least 20 mm by standard techniques; positron emissions
tomography [PET] and ultrasound are not permitted methods for tumor measurements
under this protocol.

8. Performance status of 0 or 2 on the ECOG Performance Status Scale

9. Have an estimated life expectancy of at least 12 weeks

10. Adequate organ function within 14 days prior to first berry powder dose or docetaxel
whichever occurs first, including the following - absolute neutrophil count (ANC) ≥
1.5 x 109/L, platelet count ≥ 100 x 109/L, hemoglobin ≥ 9 g/dL (≥ 5.6 mmol/L),
patients may receive packed RBC transfusion to achieve this level at the discretion
of the investigator, total bilirubin < 1.5 x upper limit of normal (ULN) unless
elevated secondary to conditions such as Gilbert's Disease, aspartate
aminotransferase (AST) < 3 x ULN (< 5 x ULN in the presence of hepatic metastases),
alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN in the presence of hepatic
metastases), alkaline phosphatase < 3.0 x ULN, calculated creatinine clearance ≥ 60
mL/min per Cockcroft and Gault formula

11. Satisfy one of the following:

- Females: non-pregnant and non-lactating; surgically sterile, post-menopausal, or
patient/partner compliant with a reliable contraceptive regimen, as determined
by the Investigator, for 4 weeks prior to screening. Patients of reproductive
potential must test negative for pregnancy at screening and must agree to use a
reliable method of birth control during the study period

- Males: surgically sterile or patient/partner must agree to use a reliable
contraceptive method, as determined by the Investigator, during the study period

- The patient is willing and able to comply with the study visit schedule and
procedures, and has geographical proximity (Investigator's discretion) that
allows follow-up specified by the protocol

- For Part 1: have discontinued all prior chemotherapies, biological therapies,
and other investigational therapies for cancer for at least 4 weeks (6 weeks for
mitomycin-C or nitrosoureas) prior to study treatment and have recovered from
the acute effects of therapy

Exclusion Criteria:

1. Part 1: More than one prior chemotherapy (single biological therapy, i.e., Erlotinib
not included) regimens (approved or experimental) for NSCLC, not counting adjuvant
and neoadjuvant treatment. A regimen is defined as two or more consecutive cycles of
treatment. Part 2: Any prior chemotherapy or biological therapy (approved or
experimental) for NSCLC including adjuvant and neoadjuvant treatments

2. Treatment with another investigational drug, biological agent, or device within 4
weeks (6 weeks for biological agents) before screening or 5 half-lives of study
agent, whichever is longer

3. Patients with treated or untreated parenchymal brain metastases or leptomeningeal
disease. Brain imaging is required for symptomatic patients to rule out brain
metastases, but is not required in asymptomatic patients

4. Patients with known pericardial effusion

5. Patients with active infection or serious concomitant systemic disorder (for example,
heart failure) incompatible with the study (at the discretion of the Investigator)

6. Presence or history of malignancy other than NSCLC, carcinoma in situ of the cervix,
or non-melanoma skin cancer. In the case of other malignancies, patients may be
considered for participation if the prior malignancies were diagnosed and
definitively treated at least two years previously with no subsequent evidence of
recurrence.

7. Presence of an underlying disease state associated with active bleeding

8. Concurrent treatment with other anticancer drugs

9. Pre-existing peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events
Version 4.0 (CTCAE) Grade 2

10. Planned concomitant participation in another clinical trial of an experimental agent,
vaccine, or device

11. Patients with any other medical conditions that in the opinion of the Investigator
would make the patient unsuitable for enrollment, or could interfere with the patient
participating in or completing the study

12. Allergy to berries